- ►oxfordjournals.org BI Rini, I Tamaskar, P Shaheen, R Salas, J … - JNCI Journal of the National Cancer Institute, 2007 - jnci.oxfordjournals.org Sunitinib is an inhibitor of the vascular endothelial growth factor and
platelet-derived growth factor receptors, and it has antitumor activity in
metastatic renal cell carcinoma and gastrointestinal stromal tumors. To ... Cited by 127 - Related articles - BL Direct - All 6 versions
- ►nih.gov TF Chu, MA Rupnick, R Kerkela, SM … - The Lancet, 2007 - Elsevier Eight of 75 (11%) patients given repeating cycles of sunitinib in the phase I/II
trial had a cardiovascular event, with congestive heart failure recorded in six
of 75 (8%). Ten of 36 (28%) patients treated at the approved sunitinib dose ... Cited by 127 - Related articles - All 44 versions
- ►endojournals.org B Biondi, DS Cooper - Endocrine Reviews, 2008 - Endocrine Soc Subclinical thyroid disease (SCTD) is defined as serum free T 4 and free T 3
levels within their respective reference ranges in the presence of abnormal
serum TSH levels. SCTD is being diagnosed more frequently in clinical ... Cited by 64 - Related articles - BL Direct - All 7 versions
- ►urosource.com [PDF] N Bhojani, C Jeldres, JJ Patard, P Perrotte, N … - European Urology, 2008 - Elsevier Side effects range from <1% to 72%. Grade 3/4 side effects are less common and
range from <1% to 13% for sorafenib, <1% to 16% for sunitinib, and 1% to 20% for
temsirolimus. Overall, sunitinib causes the most grade 3/4 side effects and ... Cited by 60 - Related articles - All 26 versions
- ►jcojournal.org V Gupta-Abramson, AB Troxel, A Nellore, K … - Journal of Clinical Oncology, 2008 - jcojournal.org Purpose Given the molecular pathophysiology of thyroid cancer and the spectrum
of kinases inhibited by sorafenib, including Raf kinase, vascular endothelial
growth factor receptors, platelet-derived growth factor receptor, and RET ... Cited by 54 - Related articles - All 7 versions
- ►alphamedpress.org LJ Costa, HA Drabkin - The oncologist, 2007 - AlphaMed Press Disclosure: HAD served on the advisory board for sorafenib and for Wyeth. No
other potential conflicts of interest were reported by the authors, planners,
reviewers, or staff managers of this article. ... List the most frequent ... Cited by 46 - Related articles - BL Direct - All 8 versions
- ►geyseco.info [PDF] SI Sherman, LJ Wirth, JP Droz, M Hofmann, L … - The New England journal of medicine, 2008 - nejm.highwire.org From the University of Texas MD Ander- son Cancer Center, Houston (SIS);
Dana−Farber Cancer Institute, Boston (LJW); Centre Léon Bérard, Lyon, France
(J.-PD); Medical School Bern, Bern, Swit- zerland (MH); Odense University ... Cited by 37 - Related articles - All 9 versions
- ►endojournals.org D Mannavola, P Coco, G Vannucchi, R … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: Sunitinib (sunitinib malate; SU11248; Sutent; Pfizer Inc., New York,
NY) is a multitarget inhibitor of tyrosine kinases for the treatment of some
human cancers. A myxedematous coma in a patient treated with sunitinib for ... Cited by 32 - Related articles - BL Direct - All 6 versions
E Wong, LS Rosen, M Mulay, A VanVugt, M … - Thyroid, 2007 - liebertonline.com Objective: Sunitinib is a novel tyrosine kinase inhibitor with antitumor and
antiangiogenic effects. An observed higher than expected rate of hypothyroidism
in sunitinib-treated patients prompted assessment of the incidence of ... Cited by 30 - Related articles - BL Direct - All 4 versions
- ►oxfordjournals.org I Tamaskar, R Bukowski, P Elson, AG … - Annals of Oncology, 2007 - Eur Soc Med Oncology Background: Sorafenib is an orally bioavailable vascular endothelial growth
factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal
cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces ... Cited by 26 - Related articles - BL Direct - All 5 versions
